NASDAQ:GEMP - Gemphire Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.14 (-4.14%)
Get New Gemphire Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GEMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GEMP

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Gemphire Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.24.

This chart shows the closing price for GEMP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Gemphire Therapeutics. This rating has held steady since May 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2019LaidlawUpgradeHold ➝ BuyHigh
8/13/2018Canaccord GenuityReiterated RatingBuy$6.00High
8/13/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$15.00Medium
8/10/2018Roth CapitalReiterated RatingBuy ➝ Neutral$30.00N/A
8/7/2018Raymond JamesDowngradeOutperform ➝ Market Perform$22.00High
7/27/2018Roth CapitalBoost Price TargetBuy$30.00 ➝ $40.00High
5/16/2018Raymond JamesInitiated CoverageOutperform$22.00High
2/1/2018HC WainwrightReiterated RatingBuy$28.00Low
1/26/2018HC WainwrightBoost Price TargetBuy ➝ Buy$22.00 ➝ $28.00Medium
12/22/2017Roth CapitalReiterated RatingBuy$30.00Medium
11/14/2017HC WainwrightReiterated RatingBuy$21.00 ➝ $22.00N/A
10/27/2017Piper Jaffray CompaniesReiterated RatingOverweight ➝ Overweight$22.00N/A
10/23/2017Canaccord GenuityReiterated RatingBuy$31.00N/A
10/19/2017Roth CapitalInitiated CoverageBuy ➝ Buy$30.00N/A
10/13/2017Canaccord GenuityReiterated RatingBuyN/A
8/31/2017HC WainwrightInitiated CoverageBuy ➝ Buy$21.00High
8/14/2017Canaccord GenuitySet Price TargetBuy$31.00Low
8/8/2017Canaccord GenuitySet Price TargetBuy$31.00Low
8/8/2017Jefferies Financial GroupLower Price TargetBuy ➝ Buy$32.00 ➝ $18.00High
8/1/2017Jefferies Financial GroupBoost Price TargetBuy$32.00High
7/26/2017Canaccord GenuitySet Price TargetBuy$31.00High
5/31/2017Jefferies Financial GroupSet Price TargetBuy$17.00Low
5/31/2017Canaccord GenuityReiterated RatingBuy$17.00High
4/26/2017Jefferies Financial GroupReiterated RatingBuy$17.00Low
4/11/2017Jefferies Financial GroupReiterated RatingBuy$17.00Low
4/10/2017Piper Jaffray CompaniesInitiated CoverageOverweight$30.00High
3/16/2017Canaccord GenuitySet Price TargetBuy$17.00High
3/16/2017Jefferies Financial GroupReiterated RatingBuy$17.00High
1/30/2017Canaccord GenuitySet Price TargetBuy$17.00N/A
1/5/2017Canaccord GenuityReiterated RatingBuy$17.00N/A
10/18/2016Jefferies Financial GroupReiterated RatingBuy$15.00 ➝ $17.00N/A
10/15/2016Canaccord GenuitySet Price TargetBuy$17.00N/A
9/16/2016Royal Bank of CanadaReiterated RatingOutperform$25.00N/A
9/6/2016LaidlawInitiated CoverageBuy$20.00N/A
8/30/2016Royal Bank of CanadaInitiated CoverageOutperform$25.00N/A
8/30/2016Jefferies Financial GroupInitiated CoverageBuy$15.00N/A
8/30/2016Canaccord GenuityInitiated CoverageBuy$17.00N/A
(Data available from 7/24/2016 forward)
Gemphire Therapeutics logo
Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and nonalcoholic fatty liver disease (NAFLD/NASH). The company is developing gemcabene, a novel, once-daily, and oral therapy for dyslipidemia conditions where patients are unable to reach their lipid lowering goals, including patients already receiving maximally tolerated statin therapy. It also completed three Phase IIb clinical trials for gemcabene in homozygous familial hypercholesterolemia (HoFH) and hypercholesterolemia, including heterozygous familial hypercholesterolemic (HeFH) and atherosclerotic cardiovascular disease (ASCVD) patients on maximally tolerated statins, and severe hypertriglyceridemia (SHTG). The company was founded in 2008 and is headquartered in Livonia, Michigan.
Read More

Today's Range

Now: $3.24
Low: $3.17
High: $3.54

50 Day Range

MA: $4.97
Low: $0.30
High: $6.38

52 Week Range

Now: $3.24
Low: $0.24
High: $1.49


1,211,698 shs

Average Volume

127,174 shs

Market Capitalization

$48.19 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Gemphire Therapeutics?

The following equities research analysts have issued reports on Gemphire Therapeutics in the last year:
View the latest analyst ratings for GEMP.

What is the current price target for Gemphire Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Gemphire Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Gemphire Therapeutics in the next year.
View the latest price targets for GEMP.

What is the current consensus analyst rating for Gemphire Therapeutics?

Gemphire Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GEMP.

What other companies compete with Gemphire Therapeutics?

How do I contact Gemphire Therapeutics' investor relations team?

Gemphire Therapeutics' physical mailing address is 17199 N. LAUREL PARK DRIVE SUITE 401, LIVONIA MI, 48152. The company's listed phone number is 734-245-1700 and its investor relations email address is [email protected] The official website for Gemphire Therapeutics is